


Novel Therapeutic Approach for the Treatment of Cancer

ID# 2020-5135



TECHNOLOGY READINESS LEVEL

2

Seeking

Investment | Licensing | Research

Keywords

- Cancer Therapeutic
- Small Molecule Drug
- Combination Therapy
- Cancer Cell Metabolism
- SLC7A11

Researchers

Sougat Misra

Assistant Research Professor

Other Researchers

Originating College

College of Agricultural Sciences

Office of Technology Management Contact

Long, Melissa
mk1137@psu.edu
814-865-5730

Technology Summary

Cystine/glutamate antiporter, SLC7A11, plays a key role in cellular cystine acquisition and redox homeostasis. Many cancer types, especially those resistant to chemo or radiotherapy, exhibit upregulated SLC7A11 expression. However, high levels of SLC7A11 overexpression in cancer cells results in rapid cell death. Due to this balance, SLC7A11 has been suggested to be a possible target for therapeutic intervention. Researchers have discovered a novel therapeutic strategy to drive overexpression of SLC7A11 in cancer cells. The researcher identified a suite of small molecule compounds that, when combined with sodium selenite or selenocystine, induces SLC7A11 expression and are cytotoxic to cancer cell types independent of cell origin, P53 status, or mutational load. Lead compound is diphenyl diselenide. While sodium selenite and selenocystine have previously been suggested to be potential therapies for cancer, the researcher determined that co-administration of diphenyl diselenide has an unexpected synergistic effect.

Application & Market Utility

The novel combination of diphenyl diselenide with sodium selenite or selenocystine may represent a new therapy option for reducing tumor growth and increasing the rate of cell cancer death. Additional compounds identified may represent additional therapeutic leads and/or starting points for small molecule optimization.

Next Steps

The researchers are seeking an industry partner or licensee to advance this pre-clinical technology.



Invent Penn State is a Commonwealth-wide initiative to spur economic development, job creation, and student career success. Invent Penn State blends entrepreneurship-focused academic programs, business startup training and incubation, funding for commercialization, and university-community collaborations to facilitate the challenging process of turning research discoveries into valuable products and services that can benefit Pennsylvanians and humankind. Learn more at invent.psu.edu.

Penn State is an equal opportunity, affirmative action employer, and is committed to providing employment opportunities to all qualified applicants without regard to race, color, religion, age, sex, sexual orientation, gender identity, national origin, disability or protected veteran status.